EA201490149A1 - Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения - Google Patents

Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения

Info

Publication number
EA201490149A1
EA201490149A1 EA201490149A EA201490149A EA201490149A1 EA 201490149 A1 EA201490149 A1 EA 201490149A1 EA 201490149 A EA201490149 A EA 201490149A EA 201490149 A EA201490149 A EA 201490149A EA 201490149 A1 EA201490149 A1 EA 201490149A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
sulfatase
iduron
production
recombinant human
Prior art date
Application number
EA201490149A
Other languages
English (en)
Other versions
EA026499B1 (ru
Inventor
Тонг-Гиу Дзин
Йо Киунг Чунг
Сонг Хоон Пайк
Йоо Чанг Парк
Дзинвоок Сео
Йонг Воон Чой
Дзонг Мун Сон
Йонг-Чул Ким
Original Assignee
Грин Кросс Корпорейшн
Медигенебио Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Грин Кросс Корпорейшн, Медигенебио Корпорейшн filed Critical Грин Кросс Корпорейшн
Publication of EA201490149A1 publication Critical patent/EA201490149A1/ru
Publication of EA026499B1 publication Critical patent/EA026499B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Abstract

Раскрыта композиция, содержащая рекомбинантную идуронат-2-сульфатазу (ИДС). Профиль гликозилирования и содержание формилглицина в композиции ИДС являются отличающимися от Элапразы, и она имеет превосходящую фармацевтическую эффективность и является более безопасной, чем общепринятый агент и, таким образом, может быть эффективно применена для терапии синдрома Хантера.
EA201490149A 2011-06-24 2012-06-15 Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения EA026499B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (2)

Publication Number Publication Date
EA201490149A1 true EA201490149A1 (ru) 2014-09-30
EA026499B1 EA026499B1 (ru) 2017-04-28

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490149A EA026499B1 (ru) 2011-06-24 2012-06-15 Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения

Country Status (28)

Country Link
US (2) US9206402B2 (ru)
EP (1) EP2723369B2 (ru)
JP (2) JP5844459B2 (ru)
KR (2) KR101158673B1 (ru)
CN (1) CN103635203B (ru)
AU (2) AU2012274215B2 (ru)
BR (1) BR112013032193A2 (ru)
CA (1) CA2839674C (ru)
CO (1) CO6862105A2 (ru)
CY (1) CY1117861T1 (ru)
DK (1) DK2723369T4 (ru)
EA (1) EA026499B1 (ru)
ES (1) ES2575377T5 (ru)
FI (1) FI2723369T4 (ru)
HK (1) HK1195731A1 (ru)
HR (1) HRP20160490T4 (ru)
HU (1) HUE027431T2 (ru)
IL (1) IL230120B (ru)
MX (1) MX341946B (ru)
MY (1) MY166647A (ru)
PE (1) PE20140734A1 (ru)
PL (1) PL2723369T5 (ru)
PT (1) PT2723369E (ru)
RS (1) RS54822B2 (ru)
SI (1) SI2723369T2 (ru)
SM (1) SMT201600194B (ru)
UA (1) UA109949C2 (ru)
WO (1) WO2012177020A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530393B2 (en) 2012-06-29 2022-12-20 Takeda Pharmaceutical Company Limited Compositions comprising iduronate-2-sulfatase

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 抗体蛋白二硫键配对分析方法
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业（上海）股份有限公司 IgG2型单抗二硫键配对分析方法
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 融合蛋白二硫键配对分析方法
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
WO2019022563A2 (ko) * 2017-07-28 2019-01-31 한미약품 주식회사 이두로네이트 2-설파타제 결합체
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR20190136271A (ko) 2018-05-30 2019-12-10 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3846780A4 (en) * 2018-09-05 2022-11-30 Sangamo Therapeutics, Inc. ENZYMATIC TESTS FOR QUANTIFICATION OF THERAPY IN PATIENTS WITH MUCOPOLYSACCHARIDOSE TYPE I OR II
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530393B2 (en) 2012-06-29 2022-12-20 Takeda Pharmaceutical Company Limited Compositions comprising iduronate-2-sulfatase

Also Published As

Publication number Publication date
EA026499B1 (ru) 2017-04-28
CY1117861T1 (el) 2017-05-17
JP2016056179A (ja) 2016-04-21
AU2016201487B2 (en) 2017-10-19
KR101158673B1 (ko) 2012-07-03
EP2723369A4 (en) 2014-12-24
SMT201600194B (it) 2016-08-31
EP2723369B2 (en) 2023-05-10
UA109949C2 (uk) 2015-10-26
MY166647A (en) 2018-07-18
CA2839674C (en) 2018-04-24
ES2575377T5 (es) 2023-10-26
US20150320843A1 (en) 2015-11-12
WO2012177020A2 (en) 2012-12-27
AU2016201487A1 (en) 2016-03-24
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
PT2723369E (pt) 2016-06-03
MX341946B (es) 2016-09-08
CN103635203A (zh) 2014-03-12
RS54822B1 (sr) 2016-10-31
WO2012177020A3 (en) 2013-04-04
SI2723369T1 (sl) 2016-09-30
AU2012274215A1 (en) 2014-02-20
CN103635203B (zh) 2016-06-08
BR112013032193A2 (pt) 2017-11-21
EP2723369A2 (en) 2014-04-30
PE20140734A1 (es) 2014-07-04
JP6000432B2 (ja) 2016-09-28
KR20160030591A (ko) 2016-03-21
HUE027431T2 (en) 2016-09-28
US20140242059A1 (en) 2014-08-28
AU2012274215B2 (en) 2015-12-10
DK2723369T3 (en) 2016-06-13
US9206402B2 (en) 2015-12-08
US9249397B2 (en) 2016-02-02
MX2013015127A (es) 2014-06-11
HK1195731A1 (zh) 2014-11-21
CA2839674A1 (en) 2012-12-27
FI2723369T4 (fi) 2023-08-31
DK2723369T4 (da) 2023-07-24
KR101910124B1 (ko) 2018-10-19
HRP20160490T1 (hr) 2016-08-12
IL230120B (en) 2020-09-30
WO2012177020A9 (en) 2013-02-14
PL2723369T5 (pl) 2024-02-05
ES2575377T3 (es) 2016-06-28
NZ620284A (en) 2015-11-27
JP2014520143A (ja) 2014-08-21
HRP20160490T4 (hr) 2023-09-15
CO6862105A2 (es) 2014-02-10
EP2723369B1 (en) 2016-04-13
JP5844459B2 (ja) 2016-01-20
SI2723369T2 (sl) 2023-08-31

Similar Documents

Publication Publication Date Title
EA201490149A1 (ru) Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения
TN2015000278A1 (en) Autotaxin inhibitors
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
GB201118656D0 (en) New compounds
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
IN2015DN00450A (ru)
MX2019005300A (es) Polimeros enlazados al proton para administracion oral.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX355446B (es) Tratamiento de rinitis.
WO2014204816A3 (en) Method for assessing protein identity and stability
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
EA032951B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
NZ704285A (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
IN2014DN09240A (ru)
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
WO2015130963A3 (en) Compositions and methods for administering insulin or insulin-like protein to the brain
EP2431049A4 (en) Pharmaceutical preparation for administration to the respiratory system Prevention of inflammatory respiratory diseases and methods of treatment or PREVENTION OF SUCH DISEASES
PH12015500853A1 (en) Method for treating type i and type ii diabetes

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM